The Latest Breaking News from Linda Marban

Duchenne Cell Therapy Shifts Its Target from the Heart to Arm Function as Decision Date Slips

Capricor will amend its deramiocel filing to seek an upper-limb indication, and says the FDA has signaled that the August 22 decision date will move.

Medical Daily · Aug 21

US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes

Capricor Therapeutics shares surged significantly after the FDA agreed to review new drug data. The company had faced setbacks last month regarding its experimental Duchenne muscular dystrophy treatment. New 24-month data will focus on improving upper limb muscle function for the drug. Analysts view the FDA's willingness to review this…

The Economic Times · Aug 14